Cargando…

Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis

BACKGROUND: Enhancer of zeste homologue 2 (EZH2) is a member of the Polycomb group of genes that is involved in epigenetic silencing and cell cycle regulation. METHODS: We studied EZH2 expression in 409 patients with colorectal cancer stages II and III. The patients were included in a randomised stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Fluge, Ø, Gravdal, K, Carlsen, E, Vonen, B, Kjellevold, K, Refsum, S, Lilleng, R, Eide, T J, Halvorsen, T B, Tveit, K M, Otte, A P, Akslen, L A, Dahl, O
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768450/
https://www.ncbi.nlm.nih.gov/pubmed/19773751
http://dx.doi.org/10.1038/sj.bjc.6605333
_version_ 1782173468913041408
author Fluge, Ø
Gravdal, K
Carlsen, E
Vonen, B
Kjellevold, K
Refsum, S
Lilleng, R
Eide, T J
Halvorsen, T B
Tveit, K M
Otte, A P
Akslen, L A
Dahl, O
author_facet Fluge, Ø
Gravdal, K
Carlsen, E
Vonen, B
Kjellevold, K
Refsum, S
Lilleng, R
Eide, T J
Halvorsen, T B
Tveit, K M
Otte, A P
Akslen, L A
Dahl, O
author_sort Fluge, Ø
collection PubMed
description BACKGROUND: Enhancer of zeste homologue 2 (EZH2) is a member of the Polycomb group of genes that is involved in epigenetic silencing and cell cycle regulation. METHODS: We studied EZH2 expression in 409 patients with colorectal cancer stages II and III. The patients were included in a randomised study, and treated with surgery alone or surgery followed by adjuvant chemotherapy. RESULTS: EZH2 expression was significantly related to increased tumour cell proliferation, as assessed by Ki-67 expression. In colon cancer, strong EZH2 expression (P=0.041) and high proliferation (⩾40%; P=0.001) were both associated with better relapse-free survival (RFS). In contrast, no such associations were found among rectal cancers. High Ki-67 staining was associated with improved RFS in colon cancer patients who received adjuvant chemotherapy (P=0.001), but not among those who were treated by surgery alone (P=0.087). In colon cancers stage III, a significant association between RFS and randomisation group was found in patients with high proliferation (P=0.046), but not in patients with low proliferation (P=0.26). Multivariate analyses of colon cancers showed that stage III (hazard ratio (HR) 4.00) and high histological grade (HR 1.80) were independent predictors of reduced RFS, whereas high proliferation indicated improved RFS (HR 0.55). CONCLUSION: Strong EZH2 expression and high proliferation are associated features and both indicate improved RFS in colon cancer, but not so in rectal cancer.
format Text
id pubmed-2768450
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-27684502010-10-20 Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis Fluge, Ø Gravdal, K Carlsen, E Vonen, B Kjellevold, K Refsum, S Lilleng, R Eide, T J Halvorsen, T B Tveit, K M Otte, A P Akslen, L A Dahl, O Br J Cancer Clinical Study BACKGROUND: Enhancer of zeste homologue 2 (EZH2) is a member of the Polycomb group of genes that is involved in epigenetic silencing and cell cycle regulation. METHODS: We studied EZH2 expression in 409 patients with colorectal cancer stages II and III. The patients were included in a randomised study, and treated with surgery alone or surgery followed by adjuvant chemotherapy. RESULTS: EZH2 expression was significantly related to increased tumour cell proliferation, as assessed by Ki-67 expression. In colon cancer, strong EZH2 expression (P=0.041) and high proliferation (⩾40%; P=0.001) were both associated with better relapse-free survival (RFS). In contrast, no such associations were found among rectal cancers. High Ki-67 staining was associated with improved RFS in colon cancer patients who received adjuvant chemotherapy (P=0.001), but not among those who were treated by surgery alone (P=0.087). In colon cancers stage III, a significant association between RFS and randomisation group was found in patients with high proliferation (P=0.046), but not in patients with low proliferation (P=0.26). Multivariate analyses of colon cancers showed that stage III (hazard ratio (HR) 4.00) and high histological grade (HR 1.80) were independent predictors of reduced RFS, whereas high proliferation indicated improved RFS (HR 0.55). CONCLUSION: Strong EZH2 expression and high proliferation are associated features and both indicate improved RFS in colon cancer, but not so in rectal cancer. Nature Publishing Group 2009-10-20 2009-09-22 /pmc/articles/PMC2768450/ /pubmed/19773751 http://dx.doi.org/10.1038/sj.bjc.6605333 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Fluge, Ø
Gravdal, K
Carlsen, E
Vonen, B
Kjellevold, K
Refsum, S
Lilleng, R
Eide, T J
Halvorsen, T B
Tveit, K M
Otte, A P
Akslen, L A
Dahl, O
Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis
title Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis
title_full Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis
title_fullStr Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis
title_full_unstemmed Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis
title_short Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis
title_sort expression of ezh2 and ki-67 in colorectal cancer and associations with treatment response and prognosis
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768450/
https://www.ncbi.nlm.nih.gov/pubmed/19773751
http://dx.doi.org/10.1038/sj.bjc.6605333
work_keys_str_mv AT flugeø expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis
AT gravdalk expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis
AT carlsene expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis
AT vonenb expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis
AT kjellevoldk expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis
AT refsums expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis
AT lillengr expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis
AT eidetj expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis
AT halvorsentb expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis
AT tveitkm expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis
AT otteap expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis
AT akslenla expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis
AT dahlo expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis